Karcinom kůry nadledvin - editorial

Z. Fryšák

Vnitr Lek 2009, 55(1):6  

Poporodní krvácení - doporučené postupy diagnostiky a léčby - editorial

M. Penka

Vnitr Lek 2009, 55(1):7-8  

Treatment of Waldenström macroglobulinaemia - the experience of one centre

Z. Adam, L. Pour, M. Krejčí, Z. Kořístek, M. Navrátil, A. Křivanová, L. Zahradová, R. Hájek

Vnitr Lek 2009, 55(1):9-17  

Waldenström macroglobulinaemia (WM) is a disease the incidence of which is approximately 10 times lower than that of multiple myeloma. The incidence of WM is reported to be respectively 0.34 per 100,000 men and 0.7 per 100,000 women. It is one of the less aggressive lymphoproliferative diseases in which therapy is indicated only when the disease symptoms start to manifest. We present a retrospective analysis of patients with the symptomatic form of WM who were treated with chemotherapy in our centre over the last 9 years, i.e. 19 WM patients (of which 7 women and 12 men). The median age upon diagnosis of the symptomatic form of WM and start of treatment...

Incidence of pancreatic carcinoma in persons with chronic pancreatitis

P. Dítě, I. Novotný, M. Přecechtělová, M. Růžička, A. Žáková, J. Trna, M. Hermannová, A. Ševčíková

Vnitr Lek 2009, 55(1):18-21  

Introduction:Pancreatic carcinoma is one of the diseases which mostly fail to be diagnosed on a timely basis, and there is no way to effectively screen patients for pancreatic carcinoma either. An option for the diagnosis of the "early glandular carcinoma" therefore resides in identification and systematic screening of patients with risk of pancreatic carcinoma. Method:We monitored 223 patients with chronic pancreatitis on a systematic basis from 1992 to 2005. During this 14-year period, we monitored the number of cigarettes smoked per year in addition to standard parametres measured by biochemical methods, endosonography,...

Diagnostika a léčba akutního peripartálního život ohrožujícího krvácení - doporučený postup

T. Binder, K. Cvachovec, V. Černý, P. Dulíček, J. Feyereisl, J. Kvasnička, A. Měchurová, M. Penka, A. Roztočil, P. Salaj, D. Seidlová, P. Ševčík, J. Valenta

Vnitr Lek 2009, 55(1):63-65  

Cardiovascular rehabilitation today

I. Karel, H. Skalická

Vnitr Lek 2009, 55(1):22-26  

The authors submit a clearly-arranged article summarizing the contemporary situation in cardiorehabilitation. They explain the term "cardiorehabilitation" as well as to whom it is assigned and who should put it in practise. It contains facts gathered from analysis of numerous randomized studies executed worldwide on thousands of patients. Benefits for various groups of patients are emphasized. The positive effect of cardiorehabilitation is proved by decrease of both morbidity and mortality, total as well as cardiovascular. The physical condition of patients, their weight, blood pressure, lipid profile, glycaemia and sensitivity to insuline, fibrinolytical...

Influencing hemostasis in substitute solution treatment

J. Máca, R. Kula, V. Chýlek

Vnitr Lek 2009, 55(1):27-36  

Hemostasis is an important intricately regulated homeostatic process. During the hospitalization a critically ill patient is often subjected to various external and internal stimuli which have abilities to influence the hemostasis. Administration of substitute solutions could be related to such an adverse effect. This paper tries to describe main mechanisms leading to impair the hemostatic balance during the fluid therapy and outline possibilities of their monitoring. The work also deals with every basic arteficial substitute solutions individually in term of their influence on coagulation. The goal was as well to point out certain controversial conclusions...

Myocardial infarction, left ventricle remodelation and cellular therapy

H. Skalická jr., J. Horák, M. Aschermann, A. Linhart, T. Paleček, P. Kobylka

Vnitr Lek 2009, 55(1):37-44  

The paper brings an overview of results of the most important and significant clinical studies dealing with the issues of bone marrow stem cell implantation in patients with acute myocardial infarction. On the world scale, research has been focused on this area for several years. Much hope is put primarily on the possibility to prevent the process of progressive remodelling of the left ventricle, the substitution of necrotic or fibrotic tissue and the resulting prevention of development and progression of heart failure. In the centre of attention are especially patients whose long-term prognosis is often very poor in spite of progress in contemporary...

Effectiveness of TNF antagonists in routine clinical practice and costs

M. Prokeš

Vnitr Lek 2009, 55(1):45-53  

A comparison of effectiveness of TNF antagonists adalimumab, infliximab and etanercept in the treatment of rheumatoid arthritis (RA) was made, which was derived from studies provided abroad based on routine clinical practice. The calculation of cost-effectiveness of each TNF antagonist for Czech Republic was made on the basis of Dutch DREAM registry of patients with RA (Kiewit et al, 2008). The prices of therapy of all three TNF antagonists are similar in the first year of treatment of patients with average weight, in the second year the price of infliximab is lower, but only in the case of patients where the doses do not reach 4 amp. of infliximab....

Adrenal cancer

M. Kršek

Vnitr Lek 2009, 55(1):54-61  

Adrenal cancer is a rare disease which is often diagnosed at a late stage and usually has a poor prognosis. This review article gives a current knowledge on the etiopathogenesis, which could lead to the improvement of therapeutic strategies and possibly outcomes of therapy. Further, clinical presentation, diagnostic approach and current treatment options in patients with adrenal cancer are summarized. The multidisciplinary approach as well as centralized care is necessary for successful management of patients with adrenal cancer and for improvement of their poor prognosis.

Coronary artery ectasia and triple-vessel disease

P. Jarkovský

Vnitr Lek 2009, 55(1):66-69  

Coronary artery ectasia (CAE) is an entity common known from 18th century. The advance in imaging methods, especially in coronary angiography, leads to more precise data about incidence of CAE among population, which is stated from 0.2 to 4.9%. Etiology of CAE is various. CAE can be rarely congenital in origin, can be associated with connective tissue disorders, and also CAE can be a iatrogenic lesion following percutaneous intervention. CAE is often accompanied by coronary artery disease (CAD). We report a case of woman with NSTEMI as a first manifestation of ischemic heart disease, with triple-vessel disease and CAE of LAD and RC, who was managed...

Z odborné literatury

Vnitr Lek 2009, 55(1):78  

Dopisy redakci

Otto Lang

Vnitr Lek 2009, 55(1):70-71  

Dopisy redakci

Josef Veselka

Vnitr Lek 2009, 55(1):72  

Vítězové a poražení z New Orleans. Od rosuvastatinu k antioxidačním vitaminům - pár postřehů ze sjezdu AHA 2008

R. Češka

Vnitr Lek 2009, 55(1):73-74  

6. kongres Medzinárodnej spoločnosti histórie nefrológie, 2.-4. októbra 2008, Taormina - Giardini Naxos (Taliansko)

M. Mydlík, K. Derzsiová

Vnitr Lek 2009, 55(1):75-77